No Data
No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The controlling subsidiary terminated the relevant freeze-dried human rabies vaccine (serum-free Vero cell) project cooperation agreement and drug clinical trials.
Gelonghui September 24th | Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced that its holding subsidiary Bohui Biopharmaceutical Co., Ltd. (formerly known as Ch Env Tech&Bio Pharmaceutical Co., Ltd., hereinafter referred to as "Langfang Bohui") and Chengdu Baoaote Biotechnology Co., Ltd. (hereinafter referred to as "Baoaote") signed a "Project Cooperation Contract" in January 2020, jointly submitted the application for clinical trials of the lyophilized human rabies vaccine (serum-free Vero cells) which Baoaote had completed the preclinical research work for. In July 2020, this vaccine obtained the "Drug Clinical Trial Batch" issued by the National Medical Products Administration.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Daguang Plasma Station obtained a single plasma license.
On September 11th, Bohui Innovation (300318.SZ) announced that its subsidiary, Bohui Biopharmaceutical (Hebei) Co., Ltd., obtained the Single Plasma Collection License issued by the Health Commission of Yunnan Province. The Da Guan Plasma Station, a subsidiary of Bohui Biopharmaceutical, has been approved and registered, and is now allowed to operate.
Bohui Innovation: 2024 Semi-Annual Report Summary
Bohui Innovation: 2024 Semi-Annual Report
Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced its performance for the first half of the year, with a net income of 27.6338 million yuan, an increase of 366.35% year-on-year.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) released the 2024 interim report. During the reporting period, the company achieved revenues of 4...
Beijing Bohui Innovation Biotechnology Group (300318.SZ): net income in the first half of the year was 276.338 million yuan, a year-on-year increase of 366.35%.
On August 29, Gelonhui reported the semi-annual report for 2024, showing a revenue of 0.487 billion yuan for the reporting period, a decrease of 7.60% year-on-year; a net income attributable to shareholders of the listed company of 27.6338 million yuan, an increase of 366.35% year-on-year; a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 26.3381 million yuan, an increase of 404.11% year-on-year; and an EPS of 0.0338 yuan.
No Data
No Data